Is sentinel lymph node biopsy needed for lentigo maligna melanoma?
Journal of Surgical Oncology · 2024
DOI: 10.1002/jso.27543 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Surgical Oncology, 2024. Verfasst von Hanna Kakish und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA. Hauptthemen laut MEDLINE: Melanoma, Skin Neoplasms, Hutchinson's Melanotic Freckle, Sentinel Lymph Node. Die Arbeit nennt 37 Literaturangaben.
Abstract (Originalsprache)
Background and Objectives Sentinel lymph node biopsy (SLNB) is an area of debate in the management of lentigo maligna melanoma (LMM). The utility of SLNB and its prognostic value in LMM have not yet been studied with large databases.
Methods
We performed a retrospective review of the National Cancer Database (2012−2020) and the Surveillance, Epidemiology, and End Results (2010−2019) database for patients with cutaneous nonmetastatic LMM with Breslow thickness >1.0 mm. Multivariable logistic regression identified factors associated with SLNB performance and sentinel lymph node (SLN) positivity. Univariable and multivariable analyses assessed overall survival (OS) and melanoma‐specific survival (MSS) based on SLNB performance and SLN status.
Results
Compared to other melanoma subtypes, LMM had lower rates of SLNB (66.6% vs. 80.0%−84.0%) and SLN positivity (11.3% vs. 18.6%−34.2%). Compared to patients who did not undergo SLNB, SLN status was significantly associated with improved OS in patients with SLN positive (HR = 0.64 [0.55−0.76]) and SLN negative (HR = 0.68 [0.49−0.94]), and worse MSS only in patients with positive SLN (HR = 3.93, p < 0.05).
Conclusion
The improved OS associated with SLNB likely implies surgical selection bias. Analysis of MSS confirms appropriate patient selection and suggests important prognostic value associated with SLN status. These results support continued SLNB for LMM patients according to standard guidelines.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Surgery, Division of Surgical Oncology, University Hospitals Cleveland Medical Center, Cleveland, Ohio, USA.
- Department of Otolaryngology-Head and Neck Surgery, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
- Department of Dermatology, University Hospitals Cleveland Medical Center, Case Western Reserve University, Cleveland, Ohio, USA.
- Division of Hematology and Oncology, University Hospitals Seidman Cancer Center, Cleveland, Ohio, USA.
Zitieren
APA
Kakish, H., Lal, T., Thuener, J. E., Bordeaux, J. S., Mangla, A., Rothermel, L. D., & Hoehn, R. S. (2024). Is sentinel lymph node biopsy needed for lentigo maligna melanoma?. Journal of Surgical Oncology. https://doi.org/10.1002/jso.27543
Vancouver
Kakish H, Lal T, Thuener JE, Bordeaux JS, Mangla A, Rothermel LD, et al. Is sentinel lymph node biopsy needed for lentigo maligna melanoma?. Journal of Surgical Oncology. 2024. doi:10.1002/jso.27543
BibTeX
@article{Kakish2024,
author = {Kakish, Hanna and Lal, Trisha and Thuener, Jason E and Bordeaux, Jeremy S and Mangla, Ankit and Rothermel, Luke D and Hoehn, Richard S},
title = {Is sentinel lymph node biopsy needed for lentigo maligna melanoma?},
journal = {Journal of Surgical Oncology},
year = {2024},
doi = {10.1002/jso.27543}
}
EUVIMED